221 related articles for article (PubMed ID: 23242809)
21. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.
Gupta M; Hendrickson AE; Yun SS; Han JJ; Schneider PA; Koh BD; Stenson MJ; Wellik LE; Shing JC; Peterson KL; Flatten KS; Hess AD; Smith BD; Karp JE; Barr S; Witzig TE; Kaufmann SH
Blood; 2012 Jan; 119(2):476-87. PubMed ID: 22080480
[TBL] [Abstract][Full Text] [Related]
22. UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice.
Hussain S; Bedekovics T; Liu Q; Hu W; Jeon H; Johnson SH; Vasmatzis G; May DG; Roux KJ; Galardy PJ
Blood; 2018 Dec; 132(24):2564-2574. PubMed ID: 30257881
[TBL] [Abstract][Full Text] [Related]
23. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
24. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.
Liu P; Ge M; Hu J; Li X; Che L; Sun K; Cheng L; Huang Y; Pilo MG; Cigliano A; Pes GM; Pascale RM; Brozzetti S; Vidili G; Porcu A; Cossu A; Palmieri G; Sini MC; Ribback S; Dombrowski F; Tao J; Calvisi DF; Chen L; Chen X
Hepatology; 2017 Jul; 66(1):167-181. PubMed ID: 28370287
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.
Fujishita T; Aoki K; Lane HA; Aoki M; Taketo MM
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13544-9. PubMed ID: 18768809
[TBL] [Abstract][Full Text] [Related]
26. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
Wang J; Boxer LM
J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
[TBL] [Abstract][Full Text] [Related]
27. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.
Tamburini J; Green AS; Bardet V; Chapuis N; Park S; Willems L; Uzunov M; Ifrah N; Dreyfus F; Lacombe C; Mayeux P; Bouscary D
Blood; 2009 Aug; 114(8):1618-27. PubMed ID: 19458359
[TBL] [Abstract][Full Text] [Related]
28. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Martin LA; Pancholi S; Farmer I; Guest S; Ribas R; Weigel MT; Thornhill AM; Ghazoui Z; A'Hern R; Evans DB; Lane HA; Johnston SR; Dowsett M
Breast Cancer Res; 2012 Oct; 14(5):R132. PubMed ID: 23075476
[TBL] [Abstract][Full Text] [Related]
30. MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development.
Sheikh BN; Lee SC; El-Saafin F; Vanyai HK; Hu Y; Pang SH; Grabow S; Strasser A; Nutt SL; Alexander WS; Smyth GK; Voss AK; Thomas T
Blood; 2015 Mar; 125(12):1910-21. PubMed ID: 25605372
[TBL] [Abstract][Full Text] [Related]
31. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.
Marzec M; Liu X; Wysocka M; Rook AH; Odum N; Wasik MA
PLoS One; 2011; 6(9):e24849. PubMed ID: 21949767
[TBL] [Abstract][Full Text] [Related]
33. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.
Astle MV; Hannan KM; Ng PY; Lee RS; George AJ; Hsu AK; Haupt Y; Hannan RD; Pearson RB
Oncogene; 2012 Apr; 31(15):1949-62. PubMed ID: 21909130
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.
Carracedo A; Ma L; Teruya-Feldstein J; Rojo F; Salmena L; Alimonti A; Egia A; Sasaki AT; Thomas G; Kozma SC; Papa A; Nardella C; Cantley LC; Baselga J; Pandolfi PP
J Clin Invest; 2008 Sep; 118(9):3065-74. PubMed ID: 18725988
[TBL] [Abstract][Full Text] [Related]
35. Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.
Nölting S; Garcia E; Alusi G; Giubellino A; Pacak K; Korbonits M; Grossman AB
J Mol Endocrinol; 2012 Oct; 49(2):79-96. PubMed ID: 22715163
[TBL] [Abstract][Full Text] [Related]
36. Cdk2 suppresses cellular senescence induced by the c-myc oncogene.
Campaner S; Doni M; Hydbring P; Verrecchia A; Bianchi L; Sardella D; Schleker T; Perna D; Tronnersjö S; Murga M; Fernandez-Capetillo O; Barbacid M; Larsson LG; Amati B
Nat Cell Biol; 2010 Jan; 12(1):54-9; sup pp 1-14. PubMed ID: 20010815
[TBL] [Abstract][Full Text] [Related]
37. mTORC1 promotes survival through translational control of Mcl-1.
Mills JR; Hippo Y; Robert F; Chen SM; Malina A; Lin CJ; Trojahn U; Wendel HG; Charest A; Bronson RT; Kogan SC; Nadon R; Housman DE; Lowe SW; Pelletier J
Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10853-8. PubMed ID: 18664580
[TBL] [Abstract][Full Text] [Related]
38. Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs.
Happo L; Phipson B; Smyth GK; Strasser A; Scott CL
Cell Death Dis; 2012 May; 3(5):e306. PubMed ID: 22573037
[TBL] [Abstract][Full Text] [Related]
39. Everolimus tablets for patients with subependymal giant cell astrocytoma.
Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
[TBL] [Abstract][Full Text] [Related]
40. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]